Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Cell Biochem. 2017 May 15;118(10):3249–3259. doi: 10.1002/jcb.25973

Figure 4. LPC-induces STAT1 binding to the CXCL10 gene promoter.

Figure 4

(A) Total RNA was extracted from HepG2 cells treated with either vehicle or 40 μM LPC at the time points indicated, cells were also treated with 40 μM LPC with or without 1 μM MLK3 inhibitor URMC-099 (URMC), 10 μM SB203580 and 100 μM STAT1 inhibitor fludarabine (Flud) for 4 hours. The mRNA expression of CXCL10 was evaluated by real-time qPCR. Fold change was determined after normalization to 18s mRNA expression, and expressed as fold change to that observed in vehicle-treated hepatocytes. (B) Schema of the human CXCL10 promoter, showing the STAT1 binding sites that were amplified by PCR. ChIP assay was performed on Huh7 cells treated with vehicle or LPC for 1 hr. Immunoprecipitated DNA was amplified by PCR demonstrating binding of STAT1 to the CXCL10 promoter with LPC treatment. Bar columns represent mean ± standard error of the mean. * p < 0.05